[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"multi-organ-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:multi-organ-disorder":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100401652","capturing-multiorgan-effects-of-covid-19-100401652",false,"NCT04510025","Capturing MultiORgan Effects of COVID-19","Assessing the Effects of Coronavirus Disease (COVID-19) on Multiple Organ Systems and Impact on Quality of Life, Functional Capacity and Mental Health","C-MORE","Inclusion Criteria:\n\n* Participant is willing and able to give informed consent for participation in the study.\n* Male or Female, aged 18 years or above.\n* Diagnosis of COVID-19 infection confirmed by detection of viral nucleic acid on reverse-transcription Polymerase Chain Reaction (RT-PCR).\n* Infection should be of moderate to severe intensity (i.e, patients with clinical signs of pneumonia such as respiratory rate \\> 30 breaths\u002Fmin; or severe respiratory distress; or SpO2 \\\u003C 90% (on room air) and admission for \\>48 hours.\n* Controls: Participants with no serological evidence of previous infection, or active\u002Fprevious symptoms suggestive of COVID-19, and who may or may not have comorbidities.\n\nExclusion Criteria:\n\n* Contraindication to MRI e.g. pregnancy, pacemaker, ferromagnetic implant, shrapnel injury, severe claustrophobia, inability to lie flat.\n* Any other significant disease or disorder which, in the opinion of the investigator, might influence the participant's ability to participate in the study.\n* Any signs of active COVID-19 infection on day of visit.\n* Significantly impaired renal function (eGFR\\\u003C30 ml\u002Fmin)",true,"ALL","18 Years","100 Years",{"count":22,"type":23},750,"ESTIMATED","OBSERVATIONAL","The C-MORE study is prospective observational holistic longitudinal study which will characterise the prevalence of multi-organ injury among COVID-19 survivors post hospital discharge and assess its effects on quality of life, exercise tolerance and mental health.",[27,28],"Coronavirus Infection","Multi-Organ Disorder",[30,31,32,33,34],"Coronavirus disease","MRI","Multi-organ injury","Quality of Life","Mental Health","RECRUITING","2025-02-04",{"date":38,"type":39},"2025-02-07","ACTUAL",{"date":41,"type":39},"2020-05-13",{"date":43,"type":23},"2026-05-01",{"name":45,"class":46},"University of Oxford","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":18,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":47},"100556394","early-phase-1-pulsed-rf-neuromodulation-and-leukocyte-rich-prp-for-refractory-low-back-pain-100556394","NCT06524531","Pulsed RF Neuromodulation and Leukocyte-Rich PRP for Refractory Low Back Pain","Safety and Efficacy of Pulsed RF Neuromodulation and Leukocyte-Rich PRP for the Treatment of Refractory Low Back Pain Due to Multifidus Dysfunction","Multifidus","Inclusion Criteria:\n\n* Refractory low back pain due to multifidus dysfunction.\n* Pain persisting for more than 6 months despite conventional treatments.\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Previous spinal surgery within the last year.\n* Current use of systemic steroids or immunosuppressive medications.\n* Known bleeding disorders or anticoagulant therapy.\n* Pregnancy or lactation.\n* Severe psychiatric or cognitive disorders.\n* Any Congenital or Non-congenital disorders","30 Years","70 Years",{"count":59,"type":23},100,"INTERVENTIONAL",[62],"EARLY_PHASE1","This clinical trial aims to check the safety and efficacy profile of pulsed radiofrequency (RF) neuromodulation combined with leukocyte-rich platelet-rich plasma (PRP) injections for the treatment of refractory low back pain due to multifidus dysfunction. The trial will compare two groups: one receiving standard physical therapy and the other receiving pulsed RF neuromodulation and physiotherapy.",[28],"2024-09-02",{"date":67,"type":39},"2024-09-19",{"date":69,"type":39},"2024-07-10",{"date":71,"type":23},"2025-12-30",{"name":73,"class":46},"Iffat Anwar Medical Complex"]